Podcasts about DS

Number 827Cleavage in Sonic games? It's more likely than you think! Plus Reggie kissing Alf, Miyamoto takes a trip to Target, our picks for a No More Heroes movie, and so much more!

Olá pessoas do UNITEDcast, no episódio dessa semana nossos podcasters comentaram uma lista de personagens de animes comuns que fazem parte do grupo LGBTQIA+. Venha conferir esta lista!   Live de gravação: https://www.youtube.com/watch?v=TIOnJaEAWRY   Participantes: Ds, Sol, Ana, Vitor   Edição: Ana Paula   – CANAL TELEGRAM: https://t.me/animeunitedbr – Mande seu Email: Email: podcast@animeunited.com.br – Apoie o UNITEDcast: Manda um PIX!!: podcast@animeunited.com.br Seja um FODEROSO do nosso Apoia-se: https://apoia.se/unitedcast Assista ao vivo no nosso Canal do Youtube! Compre na AMAZON pelo Nosso Link: https://amzn.to/2WjH5kM – Assine o UNITEDcast: Spotify: Segue a gente por lá! iTunes: Adiciona a gente lá! Google Podcasts: Assine Agora! – Links do Episódio: Twitch do DS: https://twitch.tv/dsunited Canal da Ana: https://www.youtube.com/c/CulturaAnime Grupo do Kurt https://www.facebook.com/groups/actionsecomics2 – Nos Siga: Twitter do DS: https://twitter.com/odaltonsilveira Instagram do DS: https://www.instagram.com/odaltonsilveira/ Fabebook da United: https://www.facebook.com/animeunitedoficial Twitter da United: https://twitter.com/animeunitedBR Instagram da United: https://www.instagram.com/animeunitedbr/

Grubb is joined by Tamoor to discuss Chris Pratt, From Software, and more.

when Eliana's away, Chloe will play. and she is playing with the hottest of Ds. DRAGONS that is. Join us for a VERY EXTREMELY CASUAL conversation to prime you for HOUSE OF THE DRAGON's release in August. Arah & Chloe discuss costuming, locations, licensed merch, and our greatest wishes and dreams for HOTD.  We'll be back in July with our A SONG OF ICE & FIRE prologues when Eliana returns to us. *SPOILERS: FIRE & BLOOD, PRINCESS & THE QUEEN, ROGUE PRINCE, HOUSE OF THE DRAGON, ETC, ETC   https://twitter.com/ieatzebra https://preposterousaf.podbean.com/ https://www.youtube.com/c/ieatzebraarah https://www.youtube.com/c/GrayArea Join us at our Patreon: https://www.patreon.com/girlsgonecanon   Intro music - Modern Jazz Samba by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/4063-modern-jazz-samba License: https://filmmusic.io/standard-license

Do you ever attack your body with unloving thoughts or actions? In this bonus episode of Dear Gabby, I'm sharing my live talk on developing a loving and spiritual relationship with your body. I'll guide you to witness the ways in which you could be abusing your body with negative thoughts or behaviors. Then, I'll teach you the simple mindset shift that will miraculously transform the way you see your body—and your whole being.   The following are helpful resources and books I mention within the episode:  Want more coaching from me? I created the Miracle Membership to help you design a spiritual practice you can stick to—so you can feel connected, supported and inspired every day. Each week I deliver brand new workshops, guided meditations, and so much more. And this is the best time to join! We kick off the Body Love Challenge on July 1. This challenge is like nothing I've ever done before, and it will radically transform your relationship with your body. You don't want to miss it! Click here to join.https://bit.ly/3nb985M In this episode of Dear Gabby, I reference my New York Times  bestseller May Cause Miracles. This book will teach you how to shift your thoughts to experience miraculous change in all areas of your life, including the way that you perceive your body. https://bit.ly/3Obuxb3 My newest book Happy Days: The Guided Path from Trauma to Profound Freedom and Inner Peace shares the story of how I recovered from trauma using spiritual and therapeutic tools. I used several body-based healing practices on my journey to freedom and peace. If you're interested in this topic, check out Chapter 7, “Hiding Behind the Body.” https://bit.ly/3yeiT9K If you feel you need additional support, please refer to this list of mental health resources. I'm proud of you for being here! https://bit.ly/3xTblYu This podcast is intended to educate, inspire and support you on your personal journey towards inner peace. I am not a psychologist or a medical doctor and do not offer any professional health or medical advice. If you are suffering from any psychological  or medical conditions, please seek help from  a qualified health professional.   Go to WHOOP.com and use code GABBY at checkout to save 15% today.   Start a new healthy habit today.  Visit seed.com/DEARGABBY and use code DEARGABBY to redeem 20% off your first month of Seed's DS-01™ Daily Synbiotic.     Exclusively for Dear Gabby listeners, Feel Free Botanic Tonics is offering a 40% off discount on your first purchase - just use promo code GABBY at checkout.   Produced by Dear Media.

Dr. Kristin Cederquist was born and raised in Atlanta, Georgia. After graduating with a Bachelor of Science in chemistry from Vanderbilt University in Nashville, Tennessee and a Ph.D. in chemistry from Penn State University in central Pennsylvania, she traveled to Toronto, Canada for a postdoctoral fellowship.   She's been working to develop and further diagnostic testing techniques for over 15 years and now calls San Diego, California home.    In this episode, Kristin shares:   How she became interested in studying chemistry and decided the particular type of chemistry she wanted to specialize in   How participating in research while in undergraduate school helped her understand and prepare for graduate school   The various career paths a chemistry major can prepare you for including big pharma, patent law, and the beer and wine industry   How she decided which Ph.D. programs to consider   The fact that students earn Ph.Ds in STEM for free whereas many go into debt when pursuing Masters programs in other subject areas   What is like working and living in Toronto, Canada   How she became interested in diagnostic testing   The importance of networking and having a social media presence even in STEM fields   Connect with Kristin via LinkedIn or Twitter! --- Sign up for my contact list to be the first to know about new offerings and to receive my note on all things!   You can also stay connected with Journey to Jupiter via..... Email: jetaun@jetaundavis.com Website: jetaundavis.com Instagram: @JourneyJupiter Twitter: @JourneyJupiter Facebook: @JourneyJupiter ----- Edited by Ken Inge of Dead End Hip Hop

Having a bad day? Don't worry! Hop onto the dump truck and you'll immediately feel better.

We got a fun episode this week featuring an interview with the developer behind Neon White. Don't fret, we got games to talk about too, even if they're Nontendo# Hosted by Perry Burkum (@PBurkum), Casey Gibson (@case_jets), Alex Culafi (@culafia) Intro and Hellos 0:00:00 Water/Bug Killing/Food Talk 0:01:32 Returnal (Nontendo) 0:16:54 Fallout: New Vegas 0:27:40 Neon White Interview 0:39:07 Interview End 1:22:42 Poll Results Time 1:23:37 Goodbyes 1:33:32 Thank you for listening! We can tell that you are a good-looking person. Peep the discord: https://discord.gg/XPByvgvByQ Please write in to the show at TNP@NintendoWorldReport.com Tweet us @TalkNintendoPod and Instagram us at talknintendopodcast Please consider supporting us on Patreon! For just $1 you can get access to tons of exclusive content! Check us out at www.patreon.com/nwr

Grubb is joined by Jan to discuss Hyenas, Sad Sonic, and more.

Dr. Diwakar Davar and Dr. Jason Luke, both of the University of Pittsburgh's Hillman Cancer Center, highlight key advances in early phase therapeutics and immunotherapy that were featured at the 2022 ASCO Annual Meeting and also address toxicities, including immune checkpoint inhibitor-associated myocarditis. TRANSCRIPT Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. My name is Dr. Diwakar Davar, and I'm an assistant professor of Medical Oncology, specializing in melanoma and phase 1 therapeutics at the University of Pittsburgh's Hillman Cancer Center. I am the guest host of today's podcast. My guest today is Dr. Jason Luke, a colleague and the director of the Cancer Immunotherapeutics Center at the UPMC Hillman Cancer Center here.  Today, we'll be discussing advances in early-phase therapeutics and immunotherapy that were featured at the 2022 ASCO Annual Meeting.   You'll find our full disclosures in the show notes, and the disclosures of all guests on the podcast are available on our transcripts at asco.org/podcasts.  Jason, thank you for coming on the podcast today.  Dr. Jason Luke: Thanks so much for the invitation. It was a great ASCO, and I hope everyone had a good time.  Dr. Diwakar Davar: So, onto our abstracts. So, the first one that we'll be discussing, and Jason as you know we've done this before. We'll be rapidly transitioning between phase 1 therapeutics, melanoma, and advanced phase 2 and 3 trials, but you know this is something you do very well. So Abstract 2504, it's a phase 1 trial of TIM-3 inhibitor cobomilab immunotherapy and in combination with PD-1 inhibitors nivolumab and dostarlimab. The AMBER Trial that was presented recently, and in full disclosure, both you and I actually are on this abstract. So, what do you think of this abstract? What do you think of the data that is discussed, and how do we contextualize this in relation to what needs to be done in this space?  Dr. Jason Luke: So, I think this is an exciting abstract because it brings forward what may be the next high-priority immune checkpoint to try to target in clinical oncology. To level-set, I think everybody listening will know about PD-1 and CTLA-4 as immune checkpoints. In the last year, we've had LAG-3 come forward as now a standard of care element of armamentarium in melanoma, and we look forward to further studies of LAG-3 and other tumor types as we think it should be a good partner where PD-1 is otherwise approved.  So here now, we hear about TIM-3, which is another negative regulatory checkpoint on a number of different immune subsets. And in this abstract, the antibody targeting TIM-3 was cobolimab. So, TIM-3 is a very interesting molecule. It has, what you might call, pleiotropic effects in the immune system. So, while in the context of this abstract, it was being targeted as another immune checkpoint on T cells, it's important to point out that TIM-3 has other regulatory roles in other immune subsets such as myeloid cells and very particularly dendritic cells, and that's important because it might bring in another element of the innate immune system to try to drive anti-tumor responses. So, it's an exciting target because it might be able to expand the groups of patients who could benefit from immune checkpoint blockade.  So, in this abstract, we see initially the phase 1 data of combining cobolimab, anti-TIM-3 with anti-PD-1 of a couple of different flavors. And what you could take from this abstract is that in the phase 1 setting, the drug was well-tolerated and combined well, and had pharmacokinetic properties that would be consistent with what we'd expect for this kind of a monoclonal antibody. I think we have to marry this abstract, which is really the phase 1 data about safety in pharmacokinetic (PK) to another abstract presented in the melanoma session, which showed an expansion cohort of patients who got cobolimab plus nivolumab or dostarlimab.  And there we did see a 50% response rate, albeit that there was heterogeneity of patients being treatment naïve versus treatment-experienced. So, what I would say to this on a high level is that I think these data are preliminarily exciting, suggesting that further investigation into TIM-3 may be valuable in terms of expanding the population of patients initially in melanoma, but there will data coming soon in lung cancer and in other tumor types with another novel checkpoint. And I think if we think ahead into the future, the question is probably going to end up being, which combinations of checkpoints for which patients. That's pretty exciting to think about. We've seen a lot of data of PD-1 plus other molecules, and I think some future biomarker stratification really will be necessary to know which patient would benefit the most from which of these combos, but for the time being, this is exciting data to see where the field is going to go over the next couple of years.  Dr. Diwakar Davar: Great. And I guess, to your point, one important thing to highlight from the abstract is your point about the role of the different compartments. There was actually a very interesting dose-response relationship with the highest dose of the drug not necessarily being the most effective dose, suggesting that yes, as you escalate, you may have different effects in different compartments, and maybe therefore a broad selection of doses might be required to ensure that you have optimal engagement of the optimal target.  So, the next abstract is Abstract 3007. This is the tumor-agnostic efficacy and safety of erdafitinib. So, we now know that FGFR pathway aberrations are found from 77% of all malignancies, FGFR targets are now U.S. Food and Drug Administration (FDA) approved in cholangiocarcinoma with pemigatinib, infigratinib, and as well with erdafitinib metastatic urothelial cancer. We know that these agents are not necessarily effective tests in 1 tumor type because these alterations have risen in multiple tumor types. So, the RAGNAR trial, looking at this across multiple tumor types, what do you make of the interim analysis result presented by Dr. Loriot?  Dr. Jason Luke: So, I'd say that this is probably the future of targeted therapy. And so, I think that where we have activity in 1 disease, it's very likely we would have activity in others. So, the author has described this as the largest basket trial of a molecularly defined subset that's been pursued to date. There are upwards of more than 200 patients in the study. I think it's really important, as we think about the data, to realize, though, that all FGFR alterations are not exactly the same thing. And so, in this study, they gave erdafitinib to patients with solid tumors of any FGFR altered status. And so that's FGFR1, 2, 3, 4 mutations or gene fusions. And that's a lot of heterogeneity in there actually.  And in this study, there were two-thirds fusions and one-third mutations, mostly in FGFR2 and 3. That will become relevant as we start to think about the results. On a high level, I have to say that it is impressive in pan-cancer fashion, just selecting by FGFR alteration, there's about a 30% response rate observed. I think that no matter what, that's going to be valuable considering these were patients with refractory tumors with 3 lines of prior therapy on median. I think what we need to know more is the breakdown of which specific molecular alteration and FGFR in which tumor types drove most of the benefit.  So, for example, in bladder cancer where erdafitinib is already approved, that's almost entirely an FGFR3 fusion setting. So we know the drug is effective there. And so I think there will be a further breakdown of the data. As it matures more, you really start to tease out, is it really the case that any FGFR alteration can be treated or there are some that really ought to be the high priorities that we really ought to be going after. I think it would be remiss not to also note, however, that while there's excitement about this sort of pan-cancer approach, the current generation of FGFR inhibitors are not exactly the easiest drugs to take.  And so, the in-class, hypophosphatemia and stomatitis really does lead to dose reductions in a lot of the patients. And I think that that's probably really important to emphasize is that despite the pan-tumor activity, there's still a lot of potential in this field to refine further because it's almost certainly the case that if we had less off-target toxicity, so to say, we could improve the efficacy beyond that 30% that we saw here.  All the same, I think this is exciting for the concept of a pan-cancer tumor agnostic sort of approach, and we'll really look forward to more data to come from this study over the next, hopefully, few months.  Dr. Diwakar Davar: And I guess 1 corollary to that is that we now need to start looking for FGFR alterations in multiple tumor types. So, tests, tests, tests. All right, Abstract 3004, phase 1a/1b dose escalation and expansion study of the MDM2-p53 antagonist BI 907828 in patients with multiple solid tumors including advanced, metastatic, liposarcoma. So, we've recently had data of the previously undruggable KRAS, and now we've got previously undruggable p53, for which we now have targets. So, Jason, what do you make of the p53 targeting approach, in this case, using MDM2 and this particular drug from Boehringer Ingelheim?  Dr. Jason Luke: So, I think that this is an exciting abstract exactly for the reason that you mentioned, which is that p53 has been, and unfortunately, to some degree, still remains, one of those holy grails but undruggable targets in oncology. So MDM2, for those who are listening but might not be aware, is a negative regulator of p53. So, the concept here then is if you drug it, you might release p53 to reactivate activity in that pathway, and then p53 being the guardian of the genome, so to say, potentially leading to apoptosis of cancer cells.  And so, this drug binds MDM2 and MDM2 can be amplified as a resistance mechanism in p53 and several tumor types. And so here, they showed data for the early part of a clinical trial investigating the small molecule, BI 907828, but then they focus specifically in liposarcoma, which is a disease known to be an MDM2 amplified. And so, the results were pretty interesting. The toxicity of this kind of an approach, just to note, is really in class. It leads to some gastrointestinal (GI) toxicities as well as hematologic problems, and this goes again for most regulators of the cell cycle will have these effects, whether they're CDK inhibitors or MDM2 or p53 modulators.  But I think what was very interesting, this is a disease liposarcoma where chemotherapy, functionally speaking, has no role. We, unfortunately, give it to some patients sometimes, but it has almost no activity, and they observe that in poorly differentiated liposarcomas, the response rate was about 12%, but the stable disease was quite durable. And so, I think that really is potentially a big deal because this is an orphan disease. It really lacks any other treatment. But as you zoom out from that, if you start to think about targeting amplified MDM2 in other settings, I think the activity that we see here is intriguing, and potentially suggests that we may be coming to a future where we'll have multiple, sort of, orthogonal approaches after reactivating p53. There were actually other abstracts at ASCO Annual Meeting of other molecules that were less mature also along this line.  So, I think, very exciting to take away from this, one, a potential treatment for liposarcoma for all of those patients that anybody listening actually sees, but secondarily this concept of targeting p53, which I think we'll see a lot more of over the next couple of years.  Dr. Diwakar Davar: Excellent. Moving on to the Abstract 3002, this is a phase 1, two-part multicenter, first-in-human study of DS-6000a of an antibody-drug conjugate comprising the anti-CDH6 IgG1 monoclonal antibody that is attached to a topoisomerase I inhibitor payload via a cleavable linker. And so basically, a way in which you can give topoisomerase: (1) TOP1 inhibitor, (2) CDH6-expressing cells. This was studied in advanced renal cell carcinoma (RCC) and advanced ovarian cancer in this abstract presented by Dr. Hamilton. Jason, what do you think of the results and what do you think of this approach in general, this antibody-drug conjugate (ADC) approach using novel targets as well as novel payloads?  Dr. Jason Luke: I think this is one of those that you can't help but be pretty excited about, and I think in the context of the data shown at the plenary session in breast cancer for antibody-drug conjugates (LBA3), I think this is really where the field is going to start to go. So, you mentioned that this is an antibody-drug conjugate that targets cadherin 6 or CDH6, which people will remember from biochemistry class and medical school, or something is a cell-cell adhesion molecule, really a basement membrane protein. So, the concept of targeting it really is just to go after a latch mechanism to get the molecule into the tumor where you want. And CDH expression is very high in renal cell carcinoma, upwards of 80% of samples, also high in ovarian cancer, which is why they chose those 2 tumors to go after.  So, the ADCC, and you described its structure just a little bit, but it's essentially the same backbone as trastuzumab deruxtecan, which we saw this outstanding activity for HER2 and breast cancer on the plenary, with these 8 chemotherapies moieties attached to it, but here now, targeting it instead to HER2, with this molecule now to CDH6. And I think, again, you can't help but be impressed. There were treatment responses on almost every dose level of the dose escalation in this study. There's in fact only 1 patient whose tumor was not, at least, stable disease or a PR, and I think that that just goes to show the power of truly bringing the chemotherapy in a targeted manner into the tumor microenvironment. Responses were heterogeneous. They were not super deep responses per se, but the stable disease was quite durable in the study, and the patients were going out more than 7 months. And again, realizing this is at the lower dose levels as we're increasing the dose and move this in their earlier lives of therapy is likely to be even more effective.  They did show a waterfall plot of the reduction in CA 125 for the patients with ovarian cancer that really looked quite impressive. And given that that's our clinical biomarker that we commonly follow, it may actually even more indicative of the benefit we would see as opposed to resist.  Now, again, there is some toxicity. It is a chemotherapy moiety that's conjugated to the ADCs. So, the most common toxicities were nausea, vomiting, and low platelet counts, but these are kind of toxicities that we're quite accustomed to with chemotherapy. Just to summarize, I think there's a lot of promise for this kind of antibody-drug conjugate targeting, and I think it can only be impressive that they had this amount of activity in the dose escalation of the study. [I] very much look forward to the expansion cohorts in renal and ovarian, which we'll presumably expect to see later this year, early in the next year.  Dr. Diwakar Davar: And as you alluded to, this really was parallel that ASCO, by the standing ovation given to Dr. Modi when she presented the DESTINY04 data of trastuzumab deruxtecan in HER2-low breast cancer, basically now redefining breast cancer from 4 camps, now we have to think of not just HER2 amplified or HER2-high, but also HER2-low. So yes, really have to now rethink how we classify these diseases (LBA3).  So Abstract 2509, the efficacy of anti-PD-1/PD-L1 immunotherapy in non–small cell lung cancer dependent based on CD8 and PD-L1 status. So really Dr. Galon taking us into what he has now described as the immunoscore—really a way of characterizing tumors. A way of thinking about tumors that you've also championed, Jason, in terms of this T cell-inflamed and uninflamed hypothesis. So, tell us a little bit about how these jives with your work and how you would think about lung cancer patients responding and not responding to immune checkpoint inhibitors (ICI) therapy in this context?  Dr. Jason Luke: Yeah. I think the focus quickly here on the immunoscore, so the people are aware of that, I think is really important for diving into these specific results. You have to realize our fundamental underlying predicate for immune checkpoint blockade inhibitor response is that patients have mounted an adaptive immune response. So, CD8 T-cells have gone into the tumor where they elaborate chemokines and cytokines like interferon gamma, which upregulates the expression of PD-L1 in the tumor but also in the surrounding immune cells.  So, you realize that even though antibodies are targeting PD-1, it's really that we're targeting that tumor microenvironment. So, the more robustly we can measure that, and we understand it, the more likely we are to know whether or not the patient is going to benefit. So, this is where the immunoscore comes in. The immunoscore is actually a fairly simple test. It's one slide, immunohistochemistry slide where they can stain jointly for CD8 and PD-L1 on the same slide. And that allows them to do a number of different things beyond just testing the total level of PD-L1. They can test the CD8 density, the PD-L1 expression, but then also the interaction between CD8 T-cells, their distance from each other, from PD-L1 expressing cells, and so on and so forth.  And so really [this] can give us a much more robust analysis of what all is going on in the tumor microenvironment again, off of a single slide. So here then, in this abstract, for patients with non–small cell lung cancer receiving anti-PD-1, they then compared the utility of only PD-L1 testing versus doing the immunoscore. And so, it was actually quite a large set. They had about 250 patients in their analytical set and then split about 150 or 180 or something into the training and validation sets, and they compared the immunoscore against 2 different standard PD-L1 antibodies, the 22C3 as well as the SP263. And what they saw was a high concordance for expression between PD-L1 and the immunoscore.  That's good, because, again, they're measuring PD-L1 in both of those. And so that was a good, sort of, level set. The immunoscore, however, allows them to look to 7 different parameters, again, beyond just PD-L1, as I mentioned. So, CD8 density, interaction, distance, and this kind of thing. Then in these test and training cohorts, they were able to actually split out patients who are PD-L1 positive into further groups, those that were immunoscore low and that were high. And in so doing, they were actually able to sort of dramatically predict the likely progression-free survival on PD-1 checkpoint blockade in those different non–small cell lung cancer groups.  So why is this important? Selection of patients by PD-1 has been very useful in the field of non–small cell lung cancer, but it's hardly a panacea. You're not at all assured your patient is going to do well just because they're PD-L1. And here comes a second assay that can be done in a standard of care setting. So, the immunoscore is a test. You could just order it, and that really does give you much more predictive power about who's likely to do well and who isn't. And I think this test and more broadly multi-spectral imaging is really going to become a core component to how we risk stratify and predict outcomes to checkpoint blockade and lung cancer, but broadly in other tumor types over the next couple of years.  Dr. Diwakar Davar: Okay. Now, moving on from a biomarker for PD-L1 and PD-1 to a setting in which PD-1 was just recently U.S. Food and Drug Administration (FDA)-approved, so I'll give a brief background to the trial that you've actually developed and led. And so, this is KEYNOTE-716, the abstract in question is LBA9500 (late-breaking abstract) 9500, but this is the distant metastasis-free survival (DMFS) data readout. The DMFS, distant metastasis-free survival with pembrolizumab versus placebo in the adjuvant setting for patients with stage IIB or IIC, that is high-risk node-negative melanoma and the data from the phase 3 KEYNOTE-716 study.  So, this data, at least the recurrence-free survival (RFS) data was actually earlier published, you had presented it earlier last year and also more recently this year, but it was published recently in Lancet. And we know that 716 is a study in which, for the first time ever, we have an immune checkpoint inhibitor PD-1 that was studied against placebo with the high-risk node-negative setting in stage IIB and C melanoma, demonstrated a significant RFS benefit in the setting against placebo. And now we have the DMFS readout.  Maybe you could tell us a little bit about both the RFS and the DMFS data, and why this is such an important advance for these patients.  Dr. Jason Luke: Thanks. And I agree this really is a sea change in how we thought about stratification of patients with melanoma, but I think this broadly has implications for other tumor types as well. So, in melanoma, we've historically thought of its involvement of the lymph nodes—stage III as being the high-risk disease, but we also, if you look at the outcomes from the AJCC, we see the patients with stage IIB and IIC, so deep primary lesions, actually have similar bad outcomes as those patients with stage IIIA and IIIB. And so anti-PD1 and adjuvant therapy and melanoma were originally proved for stage III, but having understood that about 5 years ago actually, started to think, well, why not also treat the patients with stage II if they're at similar risk.  And we pursued KEYNOTE-716 as you mentioned, and it read out last year as a positive trial for recurrence-free survival. And the abstract here then was to look at the impact on distant metastasis-free survival. So, while the regulatory consideration for approval, and it is approved and it's available for patients now, was based on relapse, what we really want to be preventing is the development of metastatic disease because presumably that would correlate with the eventual death of the patient from cancer.  So, in the abstract here, we see the first update for DMFS, which also was positive on its first analysis, the hazard ratio at 0.64. And so, again, very similar to the RFS benefit, showing about a 35-36% reduction in distant metastasis-free survival. And this is a theme that we've seen across adjuvant studies in melanoma, all the adjuvant studies in fact, is that the RFS improvement, the relapse-free survival hazard ratio mirrors very closely the distant metastasis-free survival ratio. We saw that again here. I think it just emphasizes that anti-PD-1 immunotherapy is highly effective in melanoma no matter what stage it's in, but rather related to the risk of death for melanoma.  And so this really has a practice changing in the field of melanoma oncology. Patients need to be referred to medical oncology early for discussion around risk stratification and consideration of adjuvant therapy—I think even at the same time that they're having resection of their primary lesion, and it even calls into  question of whether or not we should even fully be doing procedures like sentinel lymph node biopsies any longer, considering we can make the decision to give adjuvant therapy now based on the primary—albeit that's a controversial area of discussion.  And I would just love for this to start to penetrate into other disease settings. We've seen more recently, approval for neoadjuvant therapy in lung cancer and we see in kidney cancer, bladder cancer. We see adjuvant therapy in—I think we're going to see immunotherapy starting to become an important part of the armamentarium in these hard-to-treat cancers, even at the time that perioperatively before or after surgery.  So definitely a major change in the way we're thinking about stratifying patients and emphasizes that you need to get those patients with melanoma in to have that discussion around adjuvant therapy probably at the time of the primary lesion resection.  Dr. Diwakar Davar: And finally, Abstract 2507, single-cell profiling of human heart and blood in patients with checkpoint inhibitor-associated myocarditis. So, this is data from the NGH Group, Dr. Villani and colleagues are presented by Dr. Blum. We know that myocarditis is an uncommon but very serious immune related adverse event (irAE), and here in this particular dataset, this group which has done a lot of underlying work to really uncover the role of certain key phenotypes, cellular phenotypes, in the development of myocarditis it's presenting the data in the context of ICI-related myocarditis. So, what do you think of this data, what do you think of the use of checkpoint inhibitors are now, as you've said, migrated linear in the lifecycle of the patient, what do we need to be thinking about and how does this improve our understanding of both the use of the drug and what we need to be worried about?  Dr. Jason Luke: I think the toxicities of immunotherapy, while, less frequent than, say, chemotherapy, can actually be more disastrous. In the rare patients, we have extreme immune-related adverse events, there is an incidence of actually life-threatening and fatal events. And so, myocarditis, associated with checkpoint blockade, is one of those things that could be seen, and here at ASCO Annual Meeting, we saw a couple of abstracts summarizing the experience from the National Cancer Institute following myocarditis events, and then this abstract in a translational level trying to better understand what is actually going on in terms of the immune response in those myocarditis cases.  And so, I thought this was actually a very interesting abstract. There was only a small number of patients. They had 13 samples from patients who had had endomyocardial biopsies in the context of immune-related myocarditis, and you might say, well, only 13 samples, but fortunately, this is quite a rare event, less than 1% of patients who get immune checkpoint inhibitors. And what they saw was relatively unsurprising, which is that in patients who were having myocarditis, they saw an increase in T cells and in K-cells, as well as activated CD8 and CD4 T-cells.  I think what was very interesting was when they started to dig into what were the phenotypes of the cells and what were the pathways that were turned on. Again, it was not especially surprising to see that they saw increased levels of interferon signaling and immune-receptor signaling as well as motility and adhesion, but this really, I think emphasizes that there are potentially interventions beyond just the general immune-suppression approaches that we give. They could be more nuanced but perhaps more efficacious because sadly, patients do pass away when they develop this. And in their cohort of 13 patients, 3 of those patients died. And specifically, in looking in those 3 patients, they actually saw that all 3 patients had a shared T cell cluster. And they can't exactly say what it is exactly yet, but I think it's very interesting to see that because it suggests that there's probably something about the T cell response in those patients that disproportionately triggered a fatal event.  And if we can understand that better, we then may be able to really tailor our interventions in a way that is more useful. Because, frankly, the way these patients usually present is they show up in the emergency room (ER), and they're seen by an ER doctor who thinks they're having acute coronary. They ship them off to the catheterization (cath) lab. They open him up, and then they get in there, and there's nothing going on. There's no plaque. And so now, all of a sudden, everyone is quite confused. And so, if we had better ways to search for that ahead of time to be aware of it, we might have better interventions because usually what happens right at that moment is everybody gets very confused and starts calling the oncologist, and we start slapping on steroids and other immunomodulatory agents, but sometimes it's late.  So, I think this is a great abstract. It's really starting to preliminary give us an idea of what is the actual biology that underpins these terrible events, and we can hope that we can build off that over time hopefully to eventually come up with better predictors and then obviously better interventions to try to avoid these outcomes in a small but real number of patients.  Dr. Diwakar Davar: Excellent. One other point is you and I are both involved in drug development, and as we start thinking of side effects. Side effects are really on the flip side of responses in drug development. So really 1 point to make of this is that when people start developing side effects rather than, as you say, putting your hands up in the air and waving them around, 1 of the things that we should be doing in drug development is possibly biopsying these patients because we could get new PD insights into how these drugs work, why they work, and particularly which sub-populations themselves they work on, particularly in the early-drug development setting when you oftentimes don't have that many responses.  With that, thank you, Jason, for sharing your insights with us today.  Dr. Jason Luke: Thank you.  Dr. Diwakar Davar: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. So, thank you for your attention, and we will sign out.      Disclosures:  Dr. Diwakar Davar:   Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences  Consulting or Advisory Role: Instil Bio, Vedanta Biosciences  Consulting or Advisory Role (Immediate family member): Shionogi  Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences  Research Funding (Inst.): Zucero Therapeutics  Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy  Dr. Jason Luke:   Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical , Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine  Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure  Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)  Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     

       On this episode of the Absolutely Not Podcast, Heather chats with her genuine friend, Jackie Schimmel. They discuss their summer plans to move to Europe, Eat all the food, lay horizontal and release their aggression on innocent bystanders through shoving and pushing tourists. It's unhinged, it's dialed in and it's insane.    Head to squarespace.com/absolutely for a free trial, and when you're ready to launch, and use OFFER CODE: ABSOLUTELY to save 10% off your first purchase of a website or domain.   Go to Brooklinen.com today and use promo code [absolutelynot] to get $20 off your purchase of $100 or more plus free shipping.   Go to Grove.com/ABSOLUTELY today to get a free gift set worth up to fifty dollars with your first order plus free shipping.   Visit seed.com/ABSOLUTELY and use code [ABSOLUTELY] to redeem 20% off your first month of Seed's DS-01™ Daily Synbiotic.   To grab your two pills a day, head to moonjuice.com/ABSOLUTELY and use code ABSOLUTELY at checkout for 20% off.   Produced by Dear Media

Grubb is joined by Lucy James to discuss Final Fantasy 16, Activision, and more.

Hey, who put 100 Costcos underground over here? For breakfast a banana will do. (anime eps covered: 03 - The Obsessive Scientist, 04 - The Modern Ninja)

Welcome to another lengthy episode of Nerds Without Pants! Come let us keep you company for half the workday as we talk about bad video game endings, “Not E3”, and witness a Tetsuya Nomura mirror match! 00:00 – 09-06 Fish 09:14 – 2:15:27 STAGE SELECT: Top 3 Least Favorite Game Endings 2:15:38 – 3:33:48 CONSUMPTION JUNCTION: Saints Row character creation, Astria Ascending, Teenage Mutant Ninja Turtles: Shredder’s Revenge, Not E3 3:34:27 – 3:52:45 VIDEO GAME CAGE MATCH: Final Fantasy VII Remake vs Kingdom Hearts 3 3:52:54 – 4:01:57 Outro NEXT EPISODE: STAGE SELECT: What are your three favorite summons in video games? VIDEO GAME CAGE MATCH: Fatal Fury vs Evil Zone SUBMIT YOUR COMMENTS BY 8:30 CENTRAL ON 7/1 TO BE ON THE SHOW! Twitter: @NWPcast Email: NWPcast@gmail.com Our theme song “Relax” and interstitial tracks “To the Maxx” and “Moody Grooves” are written and performed by Megan McDuffee.  

In today's installment of all the best people are fragheads, I am joined by the ultimate fraghead: the one, the only MARGARET CHO!!! A 5-time Grammy-nominated comedian, Emmy-nominated actor, activist, entrepreneur, musician and artist, Margaret Cho not only does it all, she does it all…smelling GOOD. Margaret has an extensive collection, immaculate taste, and lays her head on her pillow each night smelling like a character in an Edith Wharton novel. We discuss what makes a scent a *bed scent,* the appropriate time to wear Secretions Magnifiques, what her perfect fragrance would smell like, and the niche fragrance that's scentscaping her...cats' litter boxes. Still not over this episode. Won't ever be. FRAGS MENTIONED: Celine Dion Spring in Paris, Elizabeth Arden Green Tea, Estee Lauder Pleasures, Avon Haiku, Serge Lutens Filles en Aiguilles, Le Labo Petit Grain 21, Le Labo Santal 26, Figue 15, Le Labo Cedre 11, ELdO Secretions Magnifiques, Frederic Malle Portrait of A Lady, Vilhelm Poets of Berlin, Prescriptives Calyx, Byredo Belle de Tanger, Le Labo Another 13, Byredo Super Cedar, Frederic Malle Vetiver Extraordinaire, Glossier You, JHAG Not A Perfume, Le Labo Gaiac 10, Revlon Charlie, Jean Nate, Old Spice, Estee Lauder, Dana Loves Baby Soft, Cacharel Anais Anais, China Rain, Byredo Blanche, patchouli oil, Oil of Olay, The Body Shop Dewberry, Le Labo Santal 33, Comme des Garcons Wonderwood, Escentric Molecules Molecule 01, D&G Light Blue, Escentric Molecules: M01 + Iris, M01 + Patchouli, M01 + Mandarin, Molecule 02, Molecule 03, Molecule 04; Frederic Malle: Iris Poudre, French Lover (Bois D'Orage), Musc Ravageur Hair Perfume, Carnal Flower; Comme des Garcons Celluloid, Akro Ink, Chanel Jersey, Diptyque Benjoin Boheme, Le Labo Benjoin 19, MFK Petit Matin, Le Labo Limette 37, Le Labo Rose 31, Dana Loves Fresh Lemon, Dolly Fragrance, headshop strawberry oil, Hilde Soliani Fraaagola Saalaaata, Demeter Gingerale, Atelier Clementine California, Atelier Pomelo Paradis, Robert Piguet Fracas, Elizabeth Taylor White Diamonds, Revlon Enjoli, Coty Emeraud, SJP Stash, Commodity Book, BR540, Vilhelm Poets of Berlin, DS & Durga Cowboy Grass, Nemat Amber, DKNY Delicious, Parfums MDCI Peche Cardinale, Serge Lutens Filles en Aiguilles, Xinú Monstera FOLLOW MARGARET: IG @margaret_cho, Twitter @margaretcho, TikTok: @themargaretcho SEE MARGARET ON TOUR: https://margaretcho.com/tour/ 10% OFF LUCKYSCENT ORDERS: code 'pr10' 10% OFF TWISTED LILY ORDERS: code 'perfumeroom10'

Dünya Sağlık Örgütü [[DSÖ]], Avrupa'da yaz aylarında düzenlenen festivallerin organizatörlerinin, katılımcıları maymun çiçeği hastalığına yakalanmaktan nasıl kaçınacakları konusunda bilgilendirmesi gerektiğini söylüyor. Avrupa, genişleyen bir virüs salgınının merkez üssü olmaya devam ediyor ve Dünya Sağlık Örgütü, durumun "uluslararası kamu sağlığı acil durumu" olarak kabul edilip edilmeyeceğini belirlemek için önümüzdeki hafta [[23 Haziran]] bir toplantı yapacak.

FEATURING: (00:01:14) New Business - Card Shark. Teenage Mutant Ninja Turtles: Shredder's Revenge.(00:17:57) Dicey Dungeons. Pac-Man Museum+.(00:36:29) Monster Hunter Rise: Sunbreak.(00:59:00) Mario Strikers: Battle League. Shin Megami Tensei V. (01:05:10) Listener Mail - Why is Nintendo so bad at online stores. (01:34:12) Who would win in a fight?

Sumario: Noticias. El juego de la semana: Citizen Sleeper (XBox Series, Nintendo Switch, PC, MacOS). La hora de las letras: Y no quedó ninguno. Descarga el programa.

Number 826Sonic can't kiss human women anymore? Do we have too make remakes and remasters? Are love sandwiches a scrumptious meal or a slap in the face? All these questions and many more important ones answered in this week's episode!

Ya disponible el podcast.Para descargarlo pincha aquí.Programa: 15x21Fecha de emisión: 17/06/22Duración: 2h38'47''Peso: 218,1MBVolvemos con todo un clásico de los Arcade. En esta ocasión, hemos analizado Pac-Man Museum +, un recopilatorio de la famosa saga del comecocos. En el Debate comentamos la creciente tendencia de la Industria del videojuegos por los remakes, y qué estrategia hay detrás.Como siempre, esperamos que hayáis disfrutado del programa. Volveremos con muchos más videojuegos y nuestro toque característico.¡No os lo perdáis!

Olá pessoas do UNITEDcast, no episódio dessa semana nossos podcasters comentaram uma lista de animes quase criminosos mas que todo mundo adora! Vem ser cancelado com a gente!   Live de gravação: https://www.youtube.com/watch?v=7B1CtQQQqws&t=3069s   Participantes: Ana, Kurt, Vitor   Edição: Ana Paula   – CANAL TELEGRAM: https://t.me/animeunitedbr – Mande seu Email: Email: podcast@animeunited.com.br – Apoie o UNITEDcast: Manda um PIX!!: podcast@animeunited.com.br Seja um FODEROSO do nosso Apoia-se: https://apoia.se/unitedcast Assista ao vivo no nosso Canal do Youtube! Compre na AMAZON pelo Nosso Link: https://amzn.to/2WjH5kM – Assine o UNITEDcast: Spotify: Segue a gente por lá! iTunes: Adiciona a gente lá! Google Podcasts: Assine Agora! – Links do Episódio: Twitch do DS: https://twitch.tv/dsunited Canal da Ana: https://www.youtube.com/c/CulturaAnime Grupo do Kurt https://www.facebook.com/groups/actionsecomics2 – Nos Siga: Twitter do DS: https://twitter.com/odaltonsilveira Instagram do DS: https://www.instagram.com/odaltonsilveira/ Fabebook da United: https://www.facebook.com/animeunitedoficial Twitter da United: https://twitter.com/animeunitedBR Instagram da United: https://www.instagram.com/animeunitedbr/

We could always use some parental supervision on the Voicemail Dump Truck!

We start the march to the next 300 episodes with a fun one. We get into Neon White, Wonder Boy Collection, Ys IX, plus much more! Hosted by Perry Burkum (@PBurkum), Casey Gibson (@case_jets), Alex Culafi (@culafia) How We Doin' 0:00:09 Neon White 0:11:03 Wonder Boy Collection 0:24:47 Ys IX 0:35:00 FE: Three Hopes Demo 0:52:20 Dominion 1:04:12 News Talk 1:07:21 Poll Results Time 1:18:36 Outro 1:18:16 Thank you for listening! We can tell that you are a good-looking person. Peep the discord: https://discord.gg/XPByvgvByQ Please write in to the show at TNP@NintendoWorldReport.com Tweet us @TalkNintendoPod and Instagram us at talknintendopodcast Please consider supporting us on Patreon! For just $1 you can get access to tons of exclusive content! Check us out at www.patreon.com/nwr

I love those funny little gimmick apps and face swappers! We all do! What could go wrong?

1837: Manage Your Blood Sugar & Lose Body Fat With Kelly LeVeque Kelly's background in the space and how she started her practice. (2:37) Turning your side hustle into an impactful career. (3:43) Teaching people how to support their blood sugar through the foods they are eating. (6:38) What are hunger hormones and how do they affect our behaviors? (8:39) Why it is normal to crave processed foods. (18:02) How does she address the IIFYM crowd? (20:27) Why she prefers teaching people how to fish, rather than handing them the fish. (27:14) The theory behind why protein is so satiating. (30:37) The delicate balance of teaching your kids about how food affects them. (35:26) The differences between men and women when it comes to managing blood sugar. (38:09) Why putting on muscle is the BEST way to support blood sugar balance. (40:26) The science of how we perceive sweetness and palatability. (47:33) The downstream effects of artificial sweeteners. (50:52) The importance of the first 1,000 days. (53:46) The foods she recommends eating while pregnant. (55:37) The value of cholesterol. (1:00:58) How does your nutrition change pre, during, and post-pregnancy? (1:03:53) Related Links/Products Mentioned Visit Seed for an exclusive offer for Mind Pump listeners! **Promo code MINDPUMP at checkout for 15% off your first month's supply of Seed's DS-01 Daily Synbiotic** Father's Day Special: Free Shipping on all apparel and equipment for $150.00 or more 6/10-6/24 June Promotion: Shredded Summer Bundle or MAPS HIIT 50% off! **Promo code JUNE50 at checkout** Podcast — Kelly LeVeque Body Love Every Day: Choose Your Life-Changing 21-Day Path to Food Freedom – Book by Kelly LeVeque What We Know About Eli Lilly's Experimental Weight-Loss Drug Stanford researchers explore how the human mind shapes reality NIH study finds heavily processed foods cause overeating and weight gain Protein and satiety - ScienceDirect Is diet soda better for you than regular soda? The first 1,000 days of life: The brain's window of opportunity Force of Nature Meats Prenatal Vitamins for Him + Her | WeNatal Visit Drink LMNT for an exclusive offer for Mind Pump listeners! Why Do Cows Lick Salt? (6 Common Reasons) - Informed Farmers Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Kelly LeVeque (@bewellbykelly) on Instagram Max Lugavere (@maxlugavere) on Instagram Alia J. Crum, PhD (@AliaCrum) on Twitter Robb Wolf (@dasrobbwolf) on Instagram

Sign of the Man-child Birth and Anointing (Audio) David Eells - 6/15/22 Journey to Kazakhstan Garrett Crawford - 6/10/22 (David's notes in red) I had a very vivid dream that I was inside the continental United States. I started a journey, that took me from the US and into ‘Iran', and lastly my final destination was ‘Kazakhstan'. For some reason Iran and Kazakhstan were actually inside the United States. (Kazakhstan birthed the Khazarians who are our DS Babylon faction which is in US and throughout the World. Iran represents the apostate church system in the US. The Iranians are Semites like the Jews and not Hamites like the Arabs. Their leadership apostasized and factioned against their brothers like the factions in Church and state now. And as we will see, within Kazakhstan, is the Bride that the Man-child is to be born out of. In a Dream Garrett had back in 2020, there was a virgin girl in Kazakhstan who was about to give birth to the Man-child. The Khazarians became a nomadic people and have been a criminal entity many times called the DS. To be born in Kazakhstan is to be born from Babylon as Zerubbabel, was a type of the Man-child whose name means, “Born from Babylon.") In the dream, Iran was a place where many of my unsaved childhood friends lived and had assimilated into the native culture there. (The unsaved childhood friends represent factions in apostate Christianity because they are spiritually stunted in their growth. 1 Co 13:11 When I was a child, I spake as a child, I felt as a child, I thought as a child: now that I am become a man, I have put away childish things.) I realized it was very dangerous for me to be there. (Because of their faction. Worldly Christianity is factioned and cannot see one another's points of view.)  I was not sure why I really needed to go to Kazakhstan in the dream. The dream ended with me leaving Iran and making my way to Kazakhstan. (Kazakhstan representing Babylon DS is a dangerous place because of their depopulation agenda.) There was a little house that I saw in a vision that I was to go to. When I woke up I remembered this dream and words from 2020… (The little house is the House of the David Man-child reformers that is being rebuilt.)   The Lord Induces Labor of the Man-child  Garrett Crawford - 5/25/20 (David's notes in red) In this dream I was walking up to a large coliseum. (A coliseum is a place of larger and larger circles of people representing an exponential revelation being passed on.) It was a large venue and an event was going to happen inside. I remember I was quite early for the show; they were not letting anyone in just yet. As I was in front of the coliseum, I saw David Eells walking over to me. I could not believe he was there too. It was a pleasant surprise. We had a brief conversation and as we were talking we saw a group of protesters across the street making some commotion. They kind of caught my attention but David told me not to pay them any mind. (The factious apostates in the Church and state protest and fight against the Man-child and the Bride and against God Himself.) I walked away from David and then walked back up near the coliseum and saw a man standing behind a table... But he had a lot of materials on his table and he was giving them out. Although he doesn't really exist in real life in the dream, He was David's right hand man, and assistant pastor. (He is not a physical individual person but a representation of many pastors who pass on the Man-child's wisdom and knowledge.) ... I was quite familiar with the assistant. (And we are with many of them)  He was very happy to see me and I him. We talked for a while and he had great news to tell me. (The good news of the Gospel that sets people free is always great news.) He said, "UBM has an orphanage or mission in Kazakhstan and the surrounding area. God is doing many mighty works there." (Yes He is. Kazakhstan is a land that had been conquered by the mongols but was later set free. The Mongols were a fierce and vicious people who regarded not the lives of others and were factious against all, very much like the D-S which has also conquered many lands that are now being set free. UBM does have an orphanage and mission in other countries. The pastors hand out UBM materials in the midst of peoples who are just like the vicious factious protesters mentioned above. We can't mention these people specifically for now because the faction has already tried to spiritually kill them.)  He told me the Man-child is about to be birthed and they know the young girl in whom He is coming. She was a poor virgin girl in the Church (Among the factious peoples) there in Kazakstan and she is with child. (Rev 14:1-5 And I saw, and behold, the Lamb standing on the mount Zion, and with him a hundred and forty and four thousand, having his name, and the name of his Father, written on their foreheads. … 3 and they sing as it were a new song before the throne, and before the four living creatures and the elders: and no man could learn the song save the hundred and forty and four thousand, even they that had been purchased out of the earth. 4 These are they that were not defiled with women (factions); for they are virgins. These are they that follow the Lamb whithersoever he goeth. These were purchased from among men, to be the firstfruits unto God and unto the Lamb. 5 And in their mouth was found no lie: they are without blemish.) He said they have seen the sign that He was ready to be birthed. I said "But it's too soon!" He said "No, He is coming and we have seen the sign!” (We have been shown that the Man-child is coming sooner than many believe; He will come early.) (Mat 24:42 Watch therefore: for ye know not on what day your Lord cometh.) As he was explaining all this to me in greater detail, I had a vision of the womb of the young girl and I could see the fetus of the Man-child. It was a supernatural fetus, translucent and luminous... It was not a normal flesh and blood fetus but a supernatural one. (A spiritual virgin birth. Jesus said He is coming again in the Man-child, and that by Word and Spirit. Joh 16:21-22  A woman when she is in travail hath sorrow, because her hour is come: but when she is delivered of the child, she remembereth no more the anguish, for the joy that a man is born into the world.  22  And ye therefore now have sorrow: but I will see you again, and your heart shall rejoice, and your joy no one taketh away from you.)   As he continued speaking my vision continued: I saw a hand stick what appeared to be a hooked rod like a tiny little shepherd's rod inside the womb of the mother. (David received the heart of a shepherd defending the sheep from the lion and bear before he was birthed as the anointed Man-child King.)  The rod was meant to induce labor, I saw the little rod scrape against the umbilical cord and at that very moment the little fetus made a quick reaction and assumed the position of a woman who was about to give birth. He was mimicking a woman in her labor position, knees up and legs open. It reminded me when a drill sergeant gives a command to a disciplined soldier and he stands at attention immediately. This little fetus reacted just as fast to the command. I was very impressed with the little guy. He was so little, not even a full grown baby yet but had an intelligence that was beyond his age. When I saw this vision I had trouble comprehending how such a small fetus was ready to be birthed, but labor was being induced and he was coming out regardless. (We have had many dreams of the Man-child being birthed and maturing very rapidly; even walking and talking right after birth. However this Man-child is maturing rapidly even in the womb as we will see.) (I feel like we have to be prepared that the Man-child will come sooner than we think or what he has planned for. Usually, a baby is born at 9 months but this baby was only about 5 or 6 months gestation.)   Christmas, the Man-child is Coming! David Eells - 6/7/22 On 6/7/22 I went out to sit on the porch and saw a pine tree lit up with lights that flickered on and off as droplets of water on the tree were reflecting the sun that was at just the right angle. It was beautiful and very surprising. I said, "Christmas, the Man-child is coming.” (In the natural, the holiday of Christmas has nothing to do with Jesus since it is actually the celebration of the birth of Tammuz. But the Lord will often use Christmas in dreams to represent the coming of the Man-child in our day since people relate Christmas to the birth of Jesus.) I thought, “If Michael would hurry back, I would have a witness because some wouldn't believe this.” Even though I thought God was using a natural phenomenon. I took a picture but the lights didn't show up.  Michael did come back and I showed it to him and he saw it and tried to use his phone camera but it wouldn't pick up the tiny lights even though they were very bright. I said to him, "Christmas, the Man-child is coming”. He thought it was very surprising too. Then I received the next two revelations right after...   Christmas Tree with a Dove  Vanessa Weeks - 6/6/22 (David's notes in red) I dreamed that I was in our living room and I saw a small Christmas tree in the corner. I went over to it and saw that there were several ornaments on it.  (  Eze 17:22-23  Thus saith the Lord Jehovah: I will also take of the lofty top of the cedar, and will set it; I will crop off from the topmost of its young twigs a tender one, and I will plant it upon a high and lofty mountain:  23  in the mountain of the height of Israel will I plant it; and it shall bring forth boughs, and bear fruit, and be a goodly cedar: and under it shall dwell all birds of every wing; in the shade of the branches thereof shall they dwell.  This is speaking of the Man-child reformers represented by the topmost young twigs of the cedar tree.)   I was amazed to see it, and I thought, "Why is this tree here? We don't celebrate Christmas, and Christmas was months ago." (I think this points to the birth of the Man-child ministry rather than the pagan holiday. The branches made me think of  Isa 11:1-4  And there shall come forth a shoot out of the stock of Jesse, and a branch out of his roots shall bear fruit. And the Spirit of Jehovah shall rest upon him, the spirit of wisdom and understanding, the spirit of counsel and might, the spirit of knowledge and of the fear of Jehovah. 3  And his delight shall be in the fear of Jehovah; and he shall not judge after the sight of his eyes, neither decide after the hearing of his ears; 4  but with righteousness shall he judge the poor, and decide with equity for the meek of the earth; and he shall smite the earth with the rod of his mouth; and with the breath of his lips shall he slay the wicked.) (Some mistake this for Jesus' first coming but Jesus didn't slay the wicked. It is when He returns in the Man-child that He will judge and slay the wicked. A friend had a dream that this was speaking of the David/ Man-childs.) All the ornaments were white on this very green tree, but the only one I remember was a large white dove, on a branch toward the top of the tree. (Representing the latter rain anointing of the Holy Spirit upon the Man-child reformers.) Mar 1:9  And it came to pass in those days, that Jesus came from Nazareth of Galilee, and was baptized of John in the Jordan. 10  And straightway coming up out of the water, he saw the heavens rent asunder, and the Spirit as a dove descending upon him: 11  and a voice came out of the heavens, Thou art my beloved Son, in thee I am well pleased. (And, as we saw, Jesus is coming again as a Man-child in John 16.) I thought of this dream when David talked about the evergreen tree (which represents eternal life.) and Winnie's dream of Christmas.     Christmas Eve/What is Coming   Winnie Osegueda - 6/8/22 (David's notes in red) ... I prayed and asked the Lord to show me what was coming and when I fell asleep He gave me the following dream: I dreamt that I was in a very nice suburban area and it was the evening time of Christmas Eve. (Wow Christmas again!  Another confirmation that the baby boy Man-child is coming.) I could see all the houses decorated with colorful Christmas lights throughout this neighborhood on my left. My mother's house was also located on the left side of this suburban neighborhood. (Winnie's mom is being used to represent the apostate church that all of God's elect are born out of. Many apostates are in idolatry with the world and its traditions of men represented by the celebration of Christmas which is a pagan holiday. There is a connection between the modern day Christmas tree and the ancient symbol for the fertility goddess named Asherah  Jer. 10:1-5 Hear ye the word which Jehovah speaketh unto you, O house of Israel: 2 thus saith Jehovah, Learn not the way of the nations, and be not dismayed at the signs of heaven; for the nations are dismayed at them. 3 For the customs of the peoples are vanity; for one cutteth a tree out of the forest, the work of the hands of the workman with the axe. 4 They deck it with silver and with gold; they fasten it with nails and with hammers, that it move not. 5 They are like a palm-tree, of turned work, and speak not: they must needs be borne, because they cannot go. Be not afraid of them; for they cannot do evil, neither is it in them to do good.) There was a remake of an older movie being made except it wasn't actually a movie; it was really happening. Ecclesiastes 1:9-10 The thing that hath been, it is that which shall be; and that which is done is that which shall be done: and there is no new thing under the sun. 10 Is there any thing whereof it may be said, See, this is new? it hath been already of old time, which was before us.   I recognized and remembered this old movie that they were remaking and it was starring Kiefer Sutherland (... Keifer Sutherland is an actor who played a great villain in movies in the 80s and 90s, and he was a villain in the movie in this dream as well). (The meaning of the name “Keifer” is a German nick name for someone who was quarrelsome, from an agent of Middle High German kiben, kiven 'to quarrel'. All of the factious are quarrelsome.) They brought in a new "actor" for the remake of this movie who looked just like a younger, rounder-faced version of Kiefer Sutherland. His haircut was like the one Kiefer Sutherland had in the movie "The Lost Boys," a film in which he played a vampire. ("The life of the flesh is in the blood." The spiritual vampires of the apostate churches who are “lost” children who “bite and devour” and suck the life out of people with their contentious and slanderous ways.) Because I had already seen and knew this movie very well, I knew that this Kiefer Sutherland look-alike had a plan to enter into each suburban home in this neighborhood and kill every family. I could see him lurking in the shadows of his brick house spying on the neighborhood through his window on the top floor. (Their leaders are stalkers and “peeping Tom's”.) These families were not suspicious, as he made himself appear to be trustworthy and friendly… (Rom 16:17-18  Now I beseech you, brethren, mark them that are causing the divisions and occasions of stumbling, contrary to the doctrine which ye learned: and turn away from them.  18  For they that are such serve not our Lord Christ, but their own belly; and by their smooth and fair speech they beguile the hearts of the innocent. Remember, they are actors.) I was now inside my mother's home... and this new "actor" was there as well. He handed my mother a box of Marlboro Red cigarettes and she accepted them. (She actually smoked these in real life when I was much younger.)  As soon as this actor walked off, I said "NO! NO! Why did you accept them?! Now you're marked!" and she said "I like Marlboro Reds, so if he gives me Marlboro Reds, I'm going to take them.” (The cigarettes represent receiving bad and false spirits.) (Breath and spirit are the same word and taking in smoke represents taking in an unclean spirit. If you receive slander from a factious person, you will receive that same spirits.)  She seemed to be very bothered by my objections to her receiving these cigarettes, but I knew how this movie was going to play out, so I was desperately trying to warn her to no avail. (Many in apostasy aren't heeding our warnings currently. They will have to experience judgment before they turn back to righteousness, and still, many won't repent of their wickedness and they will be killed spiritually with an eternal death.) At this point, I knew that this actor was going to come back and kill her because she was marked, and that I had to go. I couldn't stay with her there, or I would be killed as well, as much as it pained me to know what was going to happen. I didn't understand why no one else could see what was happening here. Since this movie was a remake of an old film, it should have been obvious what was going on, but it wasn't to them. (I know people who have seen this happen to others fall into the trap because of disobedience. John 12:37-40  But though he had done so many signs before them, yet they believed not on him: 38 that the word of Isaiah the prophet might be fulfilled, which he spake, Lord, who hath believed our report? And to whom hath the arm of the Lord been revealed? 39 For this cause they could not believe, for that Isaiah said again, 40 He hath blinded their eyes, and he hardened their heart; Lest they should see with their eyes, and perceive with their heart, And should turn, And I should heal them.) I left this suburban area to find an escape and I entered into the city. I stopped by a clothing store that I used to go to when I was younger. (We should not shrink back represented by visiting the younger clothing store. Heb. 10:39 But we are not of them that shrink back unto perdition; but of them that have faith unto the saving of the soul.)  I recognized one of the women that worked there in the dream, but not in real life. She was an overweight black lady with a fake ponytail. (This represents people who are walking in darkness; who feed the flesh.) She met me outside with a hug and said "Merry Christmas!" I said Merry Christmas as well ... (I don't personally celebrate Christmas, but I believe the Lord is just using this as a parable.) (A parable of judgment on the apostates at the time of the Man-child's birth.)  I noticed that I had a large overweight, gray, striped cat with me and it walked into the store. The cat wanted to stay behind and I agreed that it was best, because I could not escape what was happening with this cat tagging along. (The fat cat represents an abundance of flesh, self will and rebellion. These people will not escape the faction demons because they must be separated from the Bride and ultimately the body itself.) I thought about the verse Hebrews 12:1-2  Therefore let us also, seeing we are compassed about with so great a cloud of witnesses, lay aside every weight, and the sin which doth so easily beset us, and let us run with patience the race that is set before us, 2 looking unto Jesus the author and perfecter of our faith, who for the joy that was set before him endured the cross, despising shame, and hath sat down at the right hand of the throne of God.) (We must leave the weight of our rebellious sin nature behind, represented by the fat, grey cat, if we want to escape the judgment of faction that is coming.) The lady in the store agreed that the cat could remain there in the store, but again, I was sad because I knew what was coming and that they would not be safe if they did not escape. This "actor" would come and kill them too, including the cat. (Psa 37:38 As for transgressors, (or “rebellious”) they shall be destroyed together; The end of the wicked shall be cut off. And 2Pe 2:12  But these, as creatures without reason, born mere animals to be taken and destroyed, railing in matters whereof they are ignorant, shall in their destroying surely be destroyed.) I left the store and continued up a flight of stairs to leave this area as well, and then I woke up. The dream felt so real that when I woke up I felt like this was still happening, and I was trying to figure out what movie this was that they were trying to remake. (The people who don't learn from His-story are doomed to repeat it.) I asked the Lord for a verse by faith at random and received: Joel 2:19 (15-20 in context)  Blow the trumpet in Zion, sanctify a fast, call a solemn assembly; 16 gather the people, sanctify the assembly, assemble the old men, gather the children, and those that suck the breasts; let the bridegroom go forth from his chamber, and the bride out of her closet. (Notice: At the time of the attempted attack on the Bride she and the Man-child will be revealed and delivered.) 17 Let the priests, the ministers of the Lord, weep between the porch and the altar, and let them say, Spare thy people, O Lord, and give not thy heritage to reproach, that the nations should rule over them: wherefore should they say among the peoples, Where is their God? 18 Then was the Lord jealous for his land, and had pity on his people. 19 And the Lord answered and said unto his people, Behold, I will send you grain, and new wine, and oil, and ye shall be satisfied therewith; and I will no more make you a reproach among the nations; 20 but I will remove far off from you the northern army, and will drive it into a land barren and desolate, its forepart into the eastern sea, and its hinder part into the western sea; and its stench shall come up, and its ill savor shall come up, because it hath done great things. (The northern army is like Pharoah's army at the Red Sea. It is the end of the persecutors and the beginning of the wilderness tribulation.)   Come up Here Vanessa Weeks - 6/10/22 (David's notes in red) As I was praying in the Spirit on 6/10/22 I saw a staircase going up to heaven, and a man, which I saw from the back, was walking up it and I heard, "Come up here.” (The Man-child reformers will be caught up to the Throne of authority soon to bring God's people through the wilderness tribulation.) Rev 4:1  After these things I saw, and behold, a door opened in heaven, and the first voice that I heard, a voice as of a trumpet speaking with me, one saying, Come up here and I will show thee the things which must come to pass hereafter. (The tribulation.) Joh 1:51  And he saith unto him, Verily, verily, I say unto you, Ye shall see the heaven opened, and the angels of God ascending and descending upon the Son of man. Pro 25:6  Put not thyself forward in the presence of the king, And stand not in the place of great men: 7  For better is it that it be said unto thee, Come up hither, Than that thou shouldest be put lower in the presence of the prince, Whom thine eyes have seen.  I believe the Lord is giving us a picture of the soon anointing of the Man-Child! Thank you Father.   Vision of Bride Chosen at the Throne  Claire Pienaar - 5/25/22  (David's notes in red) I had a quick vision of myself in front of Jesus' throne. I was bigger than I am in real life, as was the throne and the setting. (I believe this “larger than life” presentation of myself in the dream denotes the corporate body of the Bride).   There was a very good looking and well-dressed man walking all around me and sizing me up. He reminded me of a very well-known fashion designer who can, just by looking at his models, make clothing that fits them perfectly. (This man represents satan, the accuser of the brethren, who always tries to get the Bride to put on garments of filth or unrighteousness.)  I had a veil over my head, but not my face. I was glowing. Jesus put out his hand to me and said, “I choose you”. Then I started telling this man to stop. I did not speak, but I was rebuking this man's words and actions in my mind. (Rev. 12:10-11 And I heard a great voice in heaven, saying, Now is come the salvation, and the power, and the kingdom of our God, and the authority of his Christ: for the accuser of our brethren is cast down, who accuseth them before our God day and night. 11 And they overcame him because of the blood of the Lamb, and because of the word of their testimony; and they loved not their life even unto death. And James 4:7 Be subject therefore unto God; but resist the devil, and he will flee from you.) The man who was sizing me up could not dress me up the way he wanted and I began glowing even more. (Rev. 19:7-8 Let us rejoice and be exceeding glad, and let us give the glory unto him: for the marriage of the Lamb is come, and his wife hath made herself ready. 8 And it was given unto her that she should array herself in fine linen, bright and pure: for the fine linen is the righteous acts of the saints.) Jesus turned to say something to Father, but I could not hear it. As I reached out to touch Jesus' hand, similar to how Esther waited for Ahasuerus to hold out the golden sceptre, I woke up.     Select LanguageAfrikaansAlbanianAmharicArabicArmenianAzerbaijaniBasqueBelarusianBengaliBosnianBulgarianCatalanCebuanoChichewaChinese (Simplified)Chinese (Traditional)CorsicanCroatianCzechDanishDutchEsperantoEstonianFilipinoFinnishFrenchFrisianGalicianGeorgianGermanGreekGujaratiHaitian CreoleHausaHawaiianHebrewHindiHmongHungarianIcelandicIgboIndonesianIrishItalianJapaneseJavaneseKannadaKazakhKhmerKinyarwandaKoreanKurdish (Kurmanji)KyrgyzLaoLatinLatvianLithuanianLuxembourgishMacedonianMalagasyMalayMalayalamMalteseMaoriMarathiMongolianMyanmar (Burmese)NepaliNorwegianOdia (Oriya)PashtoPersianPolishPortuguesePunjabiRomanianRussianSamoanScots GaelicSerbianSesothoShonaSindhiSinhalaSlovakSlovenianSomaliSpanishSundaneseSwahiliSwedishTajikTamilTatarTeluguThaiTurkishTurkmenUkrainianUrduUyghurUzbekVietnameseWelshXhosaYiddishYorubaZulu Powered by Translate Printer-friendly version

Immuno-Rejuvenation to enhance immunity Epigenetic discoveries Using Genetic testing to improve health Tracking immune health from home Vitamin c - How much is enough? Immune system impact on fact loss And so much more! . Links mentioned in this episode! . Discounts mentioned on this show at https://burnitnutrition.com/podcast129/ . . Dry Farm Wines 1 Penny Bottle Here  www.DryFarmWines.com/Burnit/ . . Get a FREE LMNT sample pack with any purchase. Limit one per customer at  http://drinklmnt.com/Burnit . . Go to http://seed.com/burnit or use code BURNIT at checkout to get 15% off your first month's supply of Seed's DS-01™ Daily Synbiotic. . .   Get Magnesium Breakthrough from BiOptimizers at www.magbreakthrough.com/burnit and get 10% OFF with code burnit10 . . Podcast Shop Page for 5th Stage Keto Body Transformation & Vitamin C Powder at https://burnitnutrition.com/shop  . Learn more about Dr. Jeffrey Bland, PHD.: Website: https://bigboldhealth.com/ . Leave me a rating & review on Apple Podcasts: https://itunes.apple.com/us/podcast/burn-it-nutrition-podcast/id1195955730?mt=2  . Follow Joseph Navarro on Instagram under @BurnitNutrition . Follow Joseph Navarro on Facebook under @BurnitNutrition . Thank You for Listening!! Please share this episode! Be the one who helps spark a transformation in your family! Feedback to share? Send email to info@BurnitNutrition.com Subscribe! Don't miss another episode! Notice of Sponsorship Affiliate Disclosure with Seed, Amazon, BiOptimizers, LMNT, Dry Farm Wines . Please read the full medical disclaimer  burnitnutrition.com/medical-disclaimer/